Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who acquired Inovio securities during this time [1]. Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [4]. - The company's DNA medicines consist of DNA plasmids and a proprietary device called "CELLECTRA," which aids in delivering these medicines into cells [4]. Product Candidate - Inovio's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [5]. - The company has indicated expectations for FDA accelerated approval and a rolling submission of the Biologics License Application (BLA) for INO-3107 by the second half of 2024, which is critical for its transition into a commercial-stage company [5]. Allegations of Misleading Statements - Throughout the Class Period, Inovio's executives allegedly made materially false and misleading statements regarding the company's operations and prospects, including deficiencies in manufacturing the CELLECTRA device and overstated regulatory and commercial prospects for INO-3107 [7]. - The company reportedly conducted multiple securities offerings during this period, generating tens of millions of dollars while disseminating positive statements about its prospects [6]. Emergence of Truth - The truth began to surface on August 8, 2024, when Inovio announced a delay in the submission of the INO-3107 BLA to mid-2025 due to manufacturing issues, resulting in a 3.1% drop in stock price [8][9]. - On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA for standard review rather than accelerated review, leading to a significant stock price decline of 24.45% [10][11].